This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Muldoon, L. L. Articles by Neuwelt, E. A. Search for Related Content PubMed PubMed Citation Articles by Muldoon, L. L. Articles by Neuwelt, E. A.

Delayed Administration of Sodium Thiosulfate in Animal Models Reduces Platinum Ototoxicity without Reduction of Antitumor Activity¹

Departments of Neurology [L. L. M., R. A. K., N. D. D., E. A. N.], Biochemistry and Molecular Biology [E. A. N.], Pharmacology [R. E. B.], and Cell and Developmental Biology [L. L. M.], and Division of Neurosurgery [E. A. N.], Oregon Health Sciences University, Portland, Oregon 97201; Department of Otolaryngology, Oregon Hearing Research Center, Portland, Oregon 97201 [R. E. B.]; Veterans Administration Medical Center, Portland Oregon 97201 [E. A. N., M. A. P.]; Greenbaum Cancer Center and Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland 21201 [E. G. Z., M. J. E.]

Platinum-based chemotherapeutic agents, such as carboplatin and cisplatin, are effective against many human tumors, but their use may be limited by a high incidence of ototoxicity. Delayed administration of the chemoprotective agent sodium thiosulfate (STS) reduces the ototoxicity of carboplatin in a guinea-pig model, when given up to 8 h after the chemotherapy, and also reduces hearing loss in patients given carboplatin with osmotic blood-brain barrier opening for treatment of brain tumors. We tested whether STS, given at times that achieved otoprotection, could impact the chemotherapeutic efficacy of carboplatin. The impact of STS was evaluated by measuring the onset of growth of LX-1 human small cell lung carcinoma s.c. xenografts in the nude rat. When STS was administered as two boluses, 2 and 6 h after treatment with carboplatin and etoposide, there was a decrease in the time to tumor progression. In contrast, when STS administration was delayed until 8 h after carboplatin/etoposide, there was no reduction in the antitumor cytotoxicity of the chemotherapy. STS infusion did not significantly affect ultrafilterable platinum pharmacokinetics in the guinea pig. To explore the potential wider applicability of STS, in a pilot study we tested its efficacy against cisplatin ototoxicity. Delayed administration of STS, 2 h after cisplatin, was protective against cisplatin-induced ototoxicity in the guinea pig model, as determined by electrophysiological measures. On the basis of these data, we suggest that delayed administration of STS may provide a mechanism to reduce the ototoxicity caused by administration of carboplatin or cisplatin for both central nervous system and systemic cancer chemotherapy.

This article has been cited by other articles:

				D. R. Freyer, L. Sung, and G. H. Reaman Prevention of Hearing Loss in Children Receiving Cisplatin Chemotherapy J. Clin. Oncol., January 10, 2009; 27(2): 317 - 318. [Full Text] [PDF]

				M. Fouladi, M. Chintagumpala, D. Ashley, S. Kellie, S. Gururangan, T. Hassall, L. Gronewold, C. F. Stewart, D. Wallace, A. Broniscer, et al. Amifostine Protects Against Cisplatin-Induced Ototoxicity in Children With Average-Risk Medulloblastoma J. Clin. Oncol., August 1, 2008; 26(22): 3749 - 3755. [Abstract] [Full Text] [PDF]

				T. M. Harned, O. Kalous, A. Neuwelt, J. Loera, L. Ji, P. Iovine, R. Sposto, E. A. Neuwelt, and C. P. Reynolds Sodium Thiosulfate Administered Six Hours after Cisplatin Does Not Compromise Antineuroblastoma Activity Clin. Cancer Res., January 15, 2008; 14(2): 533 - 540. [Abstract] [Full Text] [PDF]

				D. T. Dickey, Y. J. Wu, L. L. Muldoon, and E. A. Neuwelt Protection against Cisplatin-Induced Toxicities by N-Acetylcysteine and Sodium Thiosulfate as Assessed at the Molecular, Cellular, and in Vivo Levels J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1052 - 1058. [Abstract] [Full Text] [PDF]

				Y. J. Wu, L. L. Muldoon, and E. A. Neuwelt The Chemoprotective Agent N-Acetylcysteine Blocks Cisplatin-Induced Apoptosis through Caspase Signaling Pathway J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 424 - 431. [Abstract] [Full Text] [PDF]

				E. A. Neuwelt, M. A. Pagel, D. F. Kraemer, D. R. Peterson, and L. L. Muldoon Bone Marrow Chemoprotection without Compromise of Chemotherapy Efficacy in a Rat Brain Tumor Model J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 594 - 599. [Abstract] [Full Text] [PDF]

				K. Husain, C. Whitworth, S. Hazelrigg, and L. Rybak Carboplatin-Induced Oxidative Injury in Rat Inferior Colliculus International Journal of Toxicology, September 1, 2003; 22(5): 335 - 342. [Abstract] [PDF]

				N. D. Doolittle, L. E. Abrey, N. Ferrari, W. A. Hall, E. R. Laws, R. E. McLendon, L. L. Muldoon, D. Peereboom, D. R. Peterson, C. P. Reynolds, et al. Targeted Delivery in Primary and Metastatic Brain Tumors: Summary Report of the Seventh Annual Meeting of the Blood-Brain Barrier Disruption Consortium Clin. Cancer Res., June 1, 2002; 8(6): 1702 - 1709. [Abstract] [Full Text] [PDF]

				E. A. Neuwelt, M. A. Pagel, B. P. Hasler, T. G. Deloughery, and L. L. Muldoon Therapeutic Efficacy of Aortic Administration of N-Acetylcysteine as a Chemoprotectant against Bone Marrow Toxicity after Intracarotid Administration of Alkylators, with or without Glutathione Depletion in a Rat Model Cancer Res., November 1, 2001; 61(21): 7868 - 7874. [Abstract] [Full Text] [PDF]

				L. L. Muldoon, S. L. Walker-Rosenfeld, C. Hale, S. E. Purcell, L. C. Bennett, and E. A. Neuwelt Rescue from Enhanced Alkylator-Induced Cell Death with Low Molecular Weight Sulfur-Containing Chemoprotectants J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 797 - 805. [Abstract] [Full Text]

				N. D. Doolittle, L. L. Muldoon, R. E. Brummett, R. M. Tyson, C. Lacy, J. S. Bubalo, D. F. Kraemer, M. C. Heinrich, J. A. Henry, and E. A. Neuwelt Delayed Sodium Thiosulfate as an Otoprotectant Against Carboplatin-induced Hearing Loss in Patients with Malignant Brain Tumors Clin. Cancer Res., March 1, 2001; 7(3): 493 - 500. [Abstract] [Full Text]

				N. D. Doolittle, C. P. Anderson, W. A. Bleyer, J. G. Cairncross, T. Cloughesy, S. L. Eck, P. Guastadisegni, W. A. Hall, L. L. Muldoon, S. J. Patel, et al. Importance of dose intensity in neurooncology clinical trials: Summary Report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium Neuro-oncol, January 1, 2001; 3(1): 46 - 54. [Abstract] [PDF]